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resulta em disfunção endotelial, inﬂamação e vasculopatia. Nesse contexto, a úlcera de perna tem sido associada
à hemólise frequente em microvasos que irrigam a região
maleolar seguido de danos vasculares e hipóxia tecidual,
constituindo um potencial fator etiológico para abertura da
úlcera. Os níveis acentuados dos biomarcadores descritos
nesse estudo, como LDH, bilirrubina total/indireta, reticulócitos e AST/TGO caracterizam um processo hemolítico evidente
em pacientes UP+, enquanto os níveis reduzidos de hemácias, Hb e hematócrito evidenciam a anemia crônica causada
pela hemólise frequente, agravando o quadro clínico desses
pacientes. Ademais, as úlceras de perna incidiram mais signiﬁcativamente em pacientes com AF, genótipo caracterizado
por taxas hemolíticas mais frequentes: 12 pacientes AF UP+
(p = 0,004). Em virtude do exposto, o presente estudo reforça
o caráter hemolítico associado à etiopatogenia das úlceras de
perna em pacientes com DF.
https://doi.org/10.1016/j.htct.2020.10.076
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Diverse clinical variability among sickle cell disease
(SCD) patients opposes crises prediction, health monitoring and streamlined management. Thus, an unmet need for
objective biomarkers prevails. Exosomes are extra-cellular
nano-vesicles (50-150 nm), enriched in bioactive lipids, proteins, mRNAs and miRNAs, released by cells. They transport
molecular cargo to nearby/distant cells to affect-regulate biological processes. Recent studies by Khalyfa et al. assessed the
plasma exosome content, their sources and transcriptomics
signature as predictive marker in SCD children with acute
chest syndrome. However, the small sample sizes (32 and 33
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individuals, respectively) may not capture the clinical variability. Thus, we aim to screen large population (150 patients) with
good follow-up available at Regional Blood Center, Ribeirão
Preto using omics - proteomics and transcriptomics - of
plasma-derived exosomes to identify biomarkers in SCD. However, the grand challenges to this expansive undertaking
are: 1) establishing a R3 (reliable, robust and reproducible)
exosome extraction protocol, 2) performing high-throughput
mass-spectrometry and next generation sequencing, and 3)
establishing a reliable multi-level comparative bioinformatics platform to analyze the omics data. Here we present our
approach with an international collaborative team to resolve
these challenges and preliminary results. Exosomes from
plasma from steady state SCD patients and healthy donors
were extracted using ultracentrifugation. Exosome characterization involved size-concentration estimate by Nano Tracking
Analysis (NTA); western-blot for exosome surface marker
CD81, CD63, and CD9, and HSP70 and ALIX as internal controls;
shape conﬁrmation by transmission electron microscopy.
Interestingly, the size and concentrations were different (n = 4
each): size: 96.05+/-29.71 nm (healthy) and 65.23+/-21.7 nm
(sickle), and concentrations: 51.3+/-10.3e9 (healthy) and 107+/77.5e9 (sickle) particles/ml. Reverse-phase LC-MS/MS was
done using an Orbitrap Fusion mass-spectrometer at Butantan Institute. From the bioinformatics pipeline established at
the University of Nebraska-Lincoln, we were able to extract
expression of˜2000 proteins per sample from 8 SCD, 2 healthy
and 1 mast cell culture samples (mast cells, taken as control,
excrete exosomes in physiologic state). We identiﬁed 25 significantly down-regulated proteins in SCD samples (vs. healthy)
using t-test with equal variance (p < 0.05)–which include blood
proteins, complement proteins and immunoglobins. We identiﬁed expression of selected sno-RNAs and miRNAs: RNU
44, miR15a, miR361, miR132, miR16, miR125 and miR181 by
qRT-PCR in SCD exosomes. While we are still in process
of getting RNA-seq analysis, and the proteomics data are
preliminary, these validations are pre-requisites for establishing exosome-based omics-pipeline for biomarker discovery
for health monitoring of SCD patients, crises prediction and
assessing response-to-therapy.
https://doi.org/10.1016/j.htct.2020.10.077
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MANIFESTAÇÕES NEUROLÓGICAS EM
ADULTOS COM DOENÇA FALCIFORME SEM
ACIDENTE VASCULAR ENCEFÁLICO
ISQUÊMICO ANTERIOR: EXPERIÊNCIA DE
SERVIÇO DE REFERÊNCIA
S.C. Morais, C.C.J. Oliveira, C.T.O.F. Miranda,
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Objetivo: Identiﬁcar pacientes adultos com Doença Falciforme (DF) sem antecedente de acidente vascular encefálico
isquêmico (AVEi) que apresentaram manifestações neurológicas graves. Material e métodos: Realizada revisão de

